En Es
Categories

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry
Products Covid-19NewsSummary
Close

Covid-19 Siemens Healthineers - Laboratory Diagnostics

Clinical Laboratory

COVID-19 Severity Algorithm
Atellica COVID-19 Severity Algorithm

The Atellica COVID-19 Severity Algorithm is a model designed to help predict the potential likelihood of progression to severe disease and life-threatening multi-organ dysfunction in COVID-19 patients. In addition to patient age, D-dimer, Lactate dehydrogenase (LDH), Lymphocyte %, Eosinophil %, Creatinine, C-reactive protein (CRP), Ferritin, PT-INR, and high-sensitivity Cardiac Troponin-I are used to help predict the likelihood of disease progression to severe disease endpoints. By entering a potential patient’s lab values and age, the algorithm will generate a COVID-19 clinical severity score, including projected probability of progression to ventilator use, end-stage organ damage, and 30-day in-hospital mortality.
More details

Rapid COVID-19 Antigen Test
CLINITEST

The CLINITEST Rapid COVID-19 Antigen Test is an easy-to-use visual-read test that does not require laboratory instruments or specialized lab personnel to administer, and it delivers results in 15 minutes. This test can be used on individuals with or without COVID-19 symptoms, and can serve as an effective tool to help communities identify infected individuals and isolate outbreaks when used as part of a comprehensive mitigation strategy.
More details

SARS-CoV-2 IgG Assays
Atellica IM and ADVIA Centaur SARS-CoV-2 IgG (sCOVG) Assays

Both the Atellica IM and the ADVIA Centaur SARS-CoV-2 IgG (sCOVG) assays measure IgG antibodies to SARS-CoV-2 in the blood to help clinicians assess the level of an individual's immune response over time. The assays produce results rapidly in as few as 25 minutes on the Atellica IM Analyzer and enable accurate antibody testing on a large scale for both reference laboratories and acute care settings.
More details

SARS-CoV-2 Assay
SARS-CoV-2 Total (COV2T) Assay

The SARS-CoV-2 Total (COV2T) Assay detects both IgM and longer-lasting IgG antibodies with high sensitivity of recent and prior infection using proven antibody-bridging assay architecture to avoid false-positive results. It produces results in as little as 10 minutes on the Atellica IM Analyzer with a capacity to process up to 440 assays per hour.
More details

Interleukin-6 (IL-6) Assay
ADVIA Centaur IL6 Assay

The ADVIA Centaur IL6 Assay measures the presence of Interleukin-6 (IL-6) which is an indicator of potential severe inflammatory response in patients with confirmed SARS-CoV-2 infection. The simple blood test measures IL-6 in human serum or plasma to aid in determining the risk for hospitalized of COVID-19 patients of needing intubation with mechanical ventilation, in conjunction with clinical findings and the results of other laboratory testing.
More details

SARS-CoV-2 Assay
FTD SARS-CoV-2 Assay

The FTD SARS-CoV-2 Assay for the specific detection of the novel coronavirus causing COVID-19 is designed for high sensitivity, specificity, and inclusivity. It covers highly conserved regions within ORF1ab and N gene, and uses the same assay setup protocol and thermal-cycling profile as all FTD respiratory disease kits.
More details

SARS-CoV-2 Assay
SARS-CoV-2 Total (COV2T) Assay

The SARS-CoV-2 Total (COV2T) Assay detects both IgM and longer-lasting IgG antibodies with high sensitivity of recent and prior infection, allowing for identification of patients who have developed an adaptive immune response, which indicates recent infection or prior exposure. The assay uses a proven antibody-bridging assay architecture, which involves binding of a single SARS-CoV-2 antibody to two identical SARS-CoV-2 antigens, helping to avoid false-positive results.
More details
Close

News of Siemens Healthineers - Laboratory Diagnostics

Siemens Enters Digital Pathology Market with Proscia’s Concentriq Dx Platform

23 Mar 2022
Siemens Enters Digital Pathology Market with Proscia’s Concentriq Dx Platform
Siemens Healthineers (Erlangen, Germany) and Proscia (Philadelphia, PA, USA) have entered into a multi-year OEM agreement under which Siemens will expand its Enterprise Imaging offering towards the global digital pathology market using Proscia’s Concentriq Dx platform. With Proscia’s Concentriq Dx platform, Siemens is entering the digital pathology market to satiate the rampant demand and expand its Enterprise Imaging offering with industry-leading technology to realize the full value of digital pathology operations.
Read More

Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection

02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

05 Feb 2021
Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents
Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products, including a multi-year extension.
Read More
Close

About Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry
FaceBook Twitter Google+ Linked in
COVID-19 Severity Algorithm

COVID-19 Severity Algorithm

Model: Atellica COVID-19 Severity Algorithm
Request Information

Description:

The Atellica COVID-19 Severity Algorithm is a model designed to help predict the potential likelihood of progression to severe disease and life-threatening multi-organ dysfunction in COVID-19 patients. In addition to patient age, D-dimer, Lactate dehydrogenase (LDH), Lymphocyte %, Eosinophil %, Creatinine, C-reactive protein (CRP), Ferritin, PT-INR, and high-sensitivity Cardiac Troponin-I are used to help predict the likelihood of disease progression to severe disease endpoints.
Read More

Full Description

Description

The Atellica COVID-19 Severity Algorithm is a model designed to help predict the potential likelihood of progression to severe disease and life-threatening multi-organ dysfunction in COVID-19 patients. In addition to patient age, D-dimer, Lactate dehydrogenase (LDH), Lymphocyte %, Eosinophil %, Creatinine, C-reactive protein (CRP), Ferritin, PT-INR, and high-sensitivity Cardiac Troponin-I are used to help predict the likelihood of disease progression to severe disease endpoints. By entering a potential patient’s lab values and age, the algorithm will generate a COVID-19 clinical severity score, including projected probability of progression to ventilator use, end-stage organ damage, and 30-day in-hospital mortality. Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Siemens Healthineers - Laboratory Diagnostics (COVID-19 Severity Algorithm)
* Message

Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions